3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Prostatic Neoplasms
8
Polycystic Ovary Syndrome
7
Carcinoma, Non-Small-Cell Lung
6
Breast Neoplasms
6
Colorectal Neoplasms
5
Lung Neoplasms
4
Metabolic Syndrome
3
Insulin Resistance
3
Adenocarcinoma of Lung
3
Lymphoma, Large B-Cell, Diffuse
2
Glioblastoma
2
Carcinoma, Renal Cell
2
pCR Rate
1
Weight Gain
1
Thyroid Diseases
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Obesity
1
Non-alcoholic Fatty Liver Disease
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Motor Activity
1
Melanoma
1
Lymphoma
1
Leukoplakia
1
Leukemia, Myelomonocytic, Acute
1
Interventions
Rituximab
66
Cyclophosphamide
52
fludarabine phosphate
26
fludarabine
22
Filgrastim
21
Vincristine
19
Methotrexate
19
Melphalan
19
Doxorubicin
18
Radiotherapy
17
Etoposide
17
Prednisone
16
Tacrolimus
15
Whole-Body Irradiation
14
Mycophenolic Acid
14
Cytarabine
14
Peripheral Blood Stem Cell Transplantation
13
Gemcitabine
13
Cyclosporine
13
Antilymphocyte Serum
13
Lenalidomide
12
Busulfan
11
Bortezomib
11
Granulocyte Colony-Stimulating Factor
9
Alemtuzumab
9
sargramostim
8
Dexamethasone
8
Cord Blood Stem Cell Transplantation
8
pembrolizumab
7
ibritumomab tiuxetan
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma
×
Metformin
×
Clear all
NCT02531308
2022-09-28
DLBCL
Rush University Medical Center
Phase 2
Terminated
5 enrolled
5 charts